Scarica l'app Stockscreener
0.6752
2.82%
-0.0196
Precedente Chiudi:
$0.6948
Aprire:
$0.7055
Volume 24 ore:
1.33M
Relative Volume:
0.18
Capitalizzazione di mercato:
$7.24M
Reddito:
$5.75M
Utile/perdita netta:
$-38.96M
Rapporto P/E:
-0.0541
EPS:
-12.47
Flusso di cassa netto:
$-32.63M
1 W Prestazione:
-24.98%
1M Prestazione:
-7.06%
6M Prestazione:
-84.83%
1 anno Prestazione:
-88.91%
Intervallo 1D:
$0.675
$0.7298
Intervallo di 1 settimana:
$0.6679
$0.8642
Portata 52W:
$0.6076
$20.60
Kala Bio Inc Stock (KALA) Company Profile
Nome
Kala Bio Inc
Settore
Industria
Telefono
781-996-5252
Indirizzo
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Confronta KALA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.6752 | 7.46M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-30 | Downgrade | Mizuho | Outperform → Neutral |
| 2025-09-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-09-29 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2025-09-08 | Iniziato | Mizuho | Outperform |
| 2025-07-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-03-30 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-09-14 | Downgrade | Jefferies | Buy → Hold |
| 2020-07-23 | Iniziato | Northland Capital | Outperform |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-27 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-09 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | Iniziato | Jefferies | Buy |
Mostra tutto
Kala Bio Inc Borsa (KALA) Ultime notizie
Top Penny Stocks To ResearchDecember 4th - MarketBeat
What drives KALA BIO Inc stock priceSmall Cap Stock Opportunities & Low Risk Wealth Plans - earlytimes.in
You might want to take a look at Kala Bio Inc (KALA) now - setenews.com
Kala Bio enters securities purchase agreement with David Lazar, names him CEO - MSN
Kala Bio Shares Jump After $6 Million Funding Deal With Investor David Lazar - MSN
KALA BIO Raises $10M in Direct Offering - TipRanks
KALA BIO closes $10 million registered direct offering By Investing.com - Investing.com India
KALA BIO Raises $10 Million From Direct Offering - marketscreener.com
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - The Manila Times
KALA BIO (NASDAQ: KALA) completes $10 million offering of 10,000,000 shares to repay debt - Stock Titan
Will KALA BIO Inc. stock continue upward momentumMarket Risk Summary & Community Consensus Picks - Newser
Kala Bio raises $10 million in registered direct offering By Investing.com - Investing.com Nigeria
KALA BIO Stock (NASDAQ: KALA): New $10 Million Offering, Debt Deal and Delisting Risk – December 4, 2025 Update - ts2.tech
KALA BIO, Inc. (KALA) Stock: Surges 21.62% Amid Exciting New Offering Announcement - parameter.io
KALA Bio (KALA) Announces $10 Million Direct Stock Offering - GuruFocus
KALA BIO (KALA) Stock Explodes on Oxford Deal and $10M Offering: What December 4, 2025 Means for Investors - ts2.tech
Kala Bio announces $10 mln registered direct offering of common stock - marketscreener.com
Kala Bio Reports $10 Million Direct Stock Offering; Shares Rise - marketscreener.com
Kala Bio raises $10 million in registered direct offering - Investing.com
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - The Manila Times
KALA BIO Announces $10 Million Registered Direct Offering - GlobeNewswire
KALA BIO (NASDAQ: KALA) prices $10M registered direct sale of 10M shares at $1.00 - Stock Titan
KALA Bio’s Bold Move: A New Dawn? - timothysykes.com
Aug Mood: Will KALA BIO Inc stock continue upward momentumTrade Analysis Report & AI Driven Stock Price Forecasts - BỘ NỘI VỤ
Why Did KALA BIO Shares Jump Over 22% After Hours? - Benzinga
Will KALA BIO Inc. stock split attract more investors2025 Analyst Calls & Detailed Earnings Play Strategies - Newser
KALA BIO, Inc. (KALA) -10.9% in Intraday Trading: Shares Decline Amid Routine Activity - Stocks Telegraph
Is KALA BIO Inc. stock a buy before product launchesJuly 2025 Intraday Action & Daily Stock Trend Reports - Newser
No data: Challenges Affecting KALA Stock Movements - StocksToTrade
An analyst sees good growth prospects for Kala Bio Inc (KALA) - Setenews
KALA BIO's $6M Leadership Turnaround Boosts Shares - Mena FN
KALA BIO Inc. (KALA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kala Bio secures $6 million investment as CEO changes amid trial failure By Investing.com - Investing.com Australia
KALA Stock Soars: Buying Opportunity? - StocksToTrade
KALA BIO, Inc. (KALA) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Crude Oil Gains Over 1%; ISM Manufacturing PMI Falls In November - Benzinga
Dow Dips 200 Points; Q32 Bio Shares Jump - Benzinga
Kala Bio stock soars after $6M investment from David Lazar By Investing.com - Investing.com Nigeria
KALA’s Unexpected Surge: Unpacking the Recent Spike - timothysykes.com
Kala Bio enters into $6 million securities purchase agreement with investor David E. Lazar - marketscreener.com
KALA Secures $6M Investment, Appoints New CEO - GuruFocus
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar - The Manila Times
KALA BIO, Inc. Announces $6 Million Securities Purchase Agreement and Appointment of David E. Lazar as CEO - Quiver Quantitative
KALA BIO (NASDAQ: KALA) inks $6M securities deal, appoints David Lazar CEO and chair - Stock Titan
KALA BIO plunges 92% after phase 2 failure of eye condition drug - MSN
Is Kala Bio Inc (KALA) positioned for future growth? - Setenews
Kala Bio Inc Azioni (KALA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Kala Bio Inc Azioni (KALA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Oct 22 '25 |
Sale |
0.83 |
32,230 |
26,751 |
29,873 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Oct 23 '25 |
Sale |
0.82 |
967 |
793 |
28,906 |
| Bazemore Todd | Director |
Oct 22 '25 |
Sale |
0.83 |
47,768 |
39,647 |
35,932 |
| Brazzell Romulus K | SEE REMARKS |
Oct 22 '25 |
Sale |
0.83 |
46,748 |
38,801 |
35,952 |
| Kharabi Darius | CHIEF BUSINESS OFFICER |
Oct 22 '25 |
Sale |
0.83 |
20,806 |
17,269 |
41,760 |
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):